Identification of Immune and Hypoxia Risk Classifier to Estimate Immune Microenvironment and Prognosis in Cervical Cancer

Figure 9

Analysis of immunotherapy and chemotherapy response. (a–b) The top 20 mutated genes in the two groups; (c) the TMB in the two groups; (d–f) chemotherapeutic response in the two groups.

(a)

(b)

(c)

(d)

(e)

(f)